GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Cyclically Adjusted PS Ratio

AngioDynamics (AngioDynamics) Cyclically Adjusted PS Ratio : 0.61 (As of Apr. 30, 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Cyclically Adjusted PS Ratio?

As of today (2024-04-30), AngioDynamics's current share price is $5.82. AngioDynamics's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 was $9.61. AngioDynamics's Cyclically Adjusted PS Ratio for today is 0.61.

The historical rank and industry rank for AngioDynamics's Cyclically Adjusted PS Ratio or its related term are showing as below:

ANGO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.56   Med: 1.76   Max: 3.26
Current: 0.6

During the past years, AngioDynamics's highest Cyclically Adjusted PS Ratio was 3.26. The lowest was 0.56. And the median was 1.76.

ANGO's Cyclically Adjusted PS Ratio is ranked better than
82.8% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs ANGO: 0.60

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AngioDynamics's adjusted revenue per share data for the three months ended in Feb. 2024 was $1.869. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $9.61 for the trailing ten years ended in Feb. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AngioDynamics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AngioDynamics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Cyclically Adjusted PS Ratio Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.97 1.11 2.46 1.98 0.95

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 0.95 0.81 0.67 0.57

Competitive Comparison of AngioDynamics's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, AngioDynamics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Cyclically Adjusted PS Ratio falls into.



AngioDynamics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AngioDynamics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.82/9.61
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, AngioDynamics's adjusted Revenue per Share data for the three months ended in Feb. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=1.869/129.4194*129.4194
=1.869

Current CPI (Feb. 2024) = 129.4194.

AngioDynamics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201405 2.639 100.373 3.403
201408 2.434 100.352 3.139
201411 2.551 99.635 3.314
201502 2.422 99.032 3.165
201505 2.511 100.333 3.239
201508 2.329 100.548 2.998
201511 2.471 100.135 3.194
201602 2.403 100.040 3.109
201605 2.567 101.355 3.278
201608 2.401 101.617 3.058
201611 2.397 101.829 3.046
201702 2.306 102.779 2.904
201705 0.192 103.256 0.241
201708 2.313 103.587 2.890
201711 2.319 104.072 2.884
201802 2.239 105.052 2.758
201805 0.153 106.148 0.187
201808 1.713 106.383 2.084
201811 1.866 106.338 2.271
201902 1.746 106.649 2.119
201905 1.893 108.048 2.267
201908 1.748 108.245 2.090
201911 1.843 108.519 2.198
202002 1.836 109.139 2.177
202005 1.532 108.175 1.833
202008 1.840 109.662 2.172
202011 1.899 109.793 2.238
202102 1.856 110.968 2.165
202105 1.994 113.576 2.272
202108 1.987 115.421 2.228
202111 2.004 117.269 2.212
202202 1.892 119.703 2.046
202205 2.222 123.323 2.332
202208 2.075 124.958 2.149
202211 2.163 125.607 2.229
202302 2.043 126.928 2.083
202305 2.299 128.314 2.319
202308 1.969 129.538 1.967
202311 1.966 129.548 1.964
202402 1.869 129.419 1.869

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AngioDynamics  (NAS:ANGO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AngioDynamics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421